Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-06-28

Intellia Therapeutics, Inc.

Intellia is a biotechnology company developing in vivo CRISPR gene-editing medicines, led by lonvo-z for hereditary angioedema and nex-z for ATTR amyloidosis.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

First approval could turn promise into franchise

The five-year case rests on converting strong HAE data into regulated product revenue. If that happens on time, the business can rerate into a commercial rare-disease company with credible platform spillover; if not, much of the premium disappears.

Analysis

Thesis

If lonvo-z clears FDA and launches in 2027, Intellia can rerate from a cash-burning CRISPR platform into a real rare-disease franchise, with most 2031 value driven by HAE revenue, partial ATTR recovery and selective platform monetization rather than speculative early pipeline hopes.

Last Economy Alignment

AI helps discovery, trial operations and CMC, while the product itself is protected by biology, IP and regulation rather than fragile software pricing. The upside is real, but FDA, manufacturing and physician trust still bind scale.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.1x (from 5 most recent analyses)

Reasoning

The main upside is a category change. Today investors mostly value development progress; by 2031 they could be valuing a launched one-time HAE medicine with validated outcomes, a reusable treatment-center footprint and some follow-on editing economics. I underwrite a strong but not perfect HAE ramp, only partial ATTR recovery and modest partnering. That supports a multi-bagger, but not a moonshot, because regulation and product concentration still matter.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is now a conversion-risk story more than a pure science story. The big question is whether strong HAE data becomes a completed filing, approval, clean launch, payer access and durable physician trust before dilution, CMC friction or renewed ATTR setbacks cap the rerating.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material company-specific disclosure appeared in the last 7-10 days; the setup is still dominated by pending lonvo-z BLA completion.
The June 13 HAELO detail remains the latest fundamental update and kept efficacy, attack-free rates and tolerability supportive of the launch case.
No new financing need or fresh safety disruption has emerged since the April raise and May Q1 update, so capital remains a secondary rather than primary constraint.

Forecast update

Cleaner HAE detail and less near-term financing stress modestly improve confidence in the path from data to launch, but the core bottleneck is still regulatory conversion.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.33

They are not selling software that AI can copy overnight; they are trying to own a regulated, one-time medicine backed by hard clinical proof. AI helps them design and run faster, but the real control points are FDA trust, manufacturing quality and the care network that gets patients treated.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$26.63

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research